Item 8.01  Other Events.
On January 5, 2022, Zosano Pharma Corporation (the "Company") announced the
publication of Phase 1 clinical trial data in an article titled, "Immunogenicity
and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a
Transdermal Microneedle System" in the Journal of Vaccines and Immunology. The
data demonstrated that a low dose of a trivalent influenza vaccine administered
via the Company's transdermal microneedle system produced antibody levels that
met EMEA's three guidelines for influenza vaccine efficacy and was generally
well tolerated.
The single-center, randomized Phase 1 study enrolled 90 subjects between the
ages of 18 to 40 years to receive a trivalent influenza vaccine containing
strains A/H1N1, A/H3N2, and B. Volunteers were randomized to receive the vaccine
either via a transdermal microneedle system patch (10 µg) worn for 5 minutes,
the same patch worn for 15 minutes, or by intramuscular injection (15 µg).
Antibody levels were measured at Day 21 and compared to EMEA guidelines to
assess immunogenicity of the treatment groups. All three EMEA criteria,
including seroconversion rate, mean increase in hemagglutinin inhibition titer,
and percentage of seroprotected subjects, were met for all three influenza
strains in all treatment groups. Additionally, on day 21, most study
participants considered microneedle patch application and removal to be less
painful than intramuscular injection, and most considered the patch to be their
first choice for mode of administration. The transdermal microneedle patch was
generally well tolerated.

© Edgar Online, source Glimpses